Summary
The product Anavar 10 mg, manufactured by an unknown company, underwent independent testing to verify its potency and authenticity. The sample, identified by batch number Lot1011, was submitted by labs@musclecandy.net and analyzed by Janoshik Analytical. The analysis measured the presence of Oxandrolone, with a concentration of 12.80 mg per tablet, showing an overage of 28% compared to the labeled claim of 10 mg.
The testing process began on 19 July 2024, with the sample received on 29 July 2024, and analysis completed on 5 August 2024. While the results indicate a higher-than-expected concentration, the data underscores the importance of continuous independent testing to ensure accuracy and adherence to labeling standards. The report serves as an educational tool to promote harm reduction and informed decision-making.
Detailed Report
Product Overview
- Manufacturer: Muscle Candy
- Product Name: Anavar 10 mg
- Active Ingredient: Oxandrolone
- Batch Number: Lot1011
- Expiration Date: Not provided
- Delivery Method: Oral
Sample Acquisition and Testing
- Task Number: #46090
- Testing Ordered: 19 July 2024
- Sample Received: 29 July 2024
- Analysis Conducted By: Janoshik Analytical
- Product Submitted By: Muscle Candy
- Analysis Paid For By: Muscle Candy
Testing Results
- Specification: 10 mg per tablet (as stated on the label)
- Measured Concentration: 12.80 mg per tablet
- Accuracy: 128% (28% above the label claim)
- Variance: +28%
Verification Details
- Verification URL: https://janoshik.com/tests/46090_4BV4FXYTCYZG
Evaluation of Reseller-Submitted Testing
The higher-than-expected concentration of Oxandrolone in this sample highlights potential inconsistencies in the manufacturing process or deliberate over-dosing. Although Janoshik Analytical’s findings are transparent and credible, further independent validation is necessary to ensure consistent product quality across multiple batches. Reseller-submitted tests often provide valuable data but may reflect selectively chosen samples, warranting cautious interpretation.
Conclusion
The analysis reveals that the tested batch of Anavar 10 mg contains 12.80 mg of Oxandrolone per tablet, exceeding the label claim by 28%. This overage underscores the need for additional scrutiny of product consistency and quality assurance in the manufacturing process. This report aims to support educational and harm reduction efforts, helping consumers make informed choices.
Disclaimer
This report is published for educational and harm reduction purposes. Reseller-submitted testing may involve inherent biases; however, it can still provide useful data when critically assessed alongside third-party or independent results. Readers are encouraged to use this information responsibly.
